Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 4, 2012, Pages 376-384

  Bayrak, Ahmet ^a   Bayrak, Tülin ^a   Lale Tokgozoglu S ^a   Volkan Salanci, Bilge ^a   Deniz, Ali ^a   Yavuz, Bünyamin ^a   Alikaşifoǧlu, Mehmet ^a   Demirpençe, Ediz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Homocysteine thiolactonase; Paraoxonase; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DNA; HOMOCYSTEINE THIOLACTONASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DNA ISOLATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; SPECTROPHOTOMETRY;

AGED; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BASE SEQUENCE; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84860343877     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.11320     Document Type: Article

References (49)

1. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol, 2004; 11: 412-419
2. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ: On the physiological role(s) of the paraoxonases. Chem Biol Interact, 1999; 119: 379-388
3. Khersonsky O, Tawfik DS: Structure-reactivity studies of serum PON1 suggest that its native activity is lactonase. Biochemistry, 2005; 44: 6371-6382
4. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett, 1998; 423: 57-60
5. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett, 1991; 286: 152-154
6. Mackness MI, Durrington PN, Mackness B: How highdensity lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol, 2000; 11: 383-388
7. Rosenblat M, Vaya J, Shih DM, Aviram M: Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells. Atherosclerosis, 2005; 179: 69-77
8. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1- knockout mice. Free Radic Biol Med, 2003; 34: 774-784
9. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM: Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation, 2002; 106: 484-490
10. Jakubowski H: Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J Biol Chem, 2000; 275: 3957-3962
11. Beltowski J: Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig Med Dosw, 2005; 59: 392-404
12. Domagala TB, Lacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H: The correlation of homocysteine- thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-le-grand), 2006; 31: 4-10
13. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI: Paraoxonase status in coronary artery disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol, 2001; 21: 1451-1457
14. Mackness M, Mackness B: Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Rad Biol Med, 2004; 37: 1317-1323
15. Imai Y, Marita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y: Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis, 2000; 149: 435-442
16. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J: The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology, 2010; 61: 157-165
17. van Himbergen TM, van der Schouw YT, Voorbij HA, van Tits LJ, Stalenhoef AF, Peeters PH, Roest M: Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis, 2008; 199: 408-414
18. Sanghera DK, Aston CE, Saha N, Kamboh MI: DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet, 1998; 62: 36-44
19. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL: Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA, 2008; 299: 1265-1276
20. Birjmohun RS, Vergeer M, Stroes ES, Sandhu MS, Ricketts SL, Tanck MW, Wareham NJ, Jukema JW, Kastelein JJ, Khaw KT, Boekholdt SM: Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One, 2009; 4: e6809
21. Kuremoto K, Watanabe Y, Ohmura H, Shimada K, Mokuno H, Daida H: R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects. J Atheroscler Thromb, 2003; 10: 85-92
22. Richter RJ, Furlong CE: Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics, 1999; 9: 745-753
23. Mohamed RH, Mohamed RH, Karam RA, Abd El-Aziz TA: The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem, 2010; 43: 553-558
24. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol, 2000; 20: 2441-2447
25. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, Heagerty PJ, Furlong CE: Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol, 2003; 23: 1465-1471
26. Nakanishi M, Takanami Y, Maruyama T, Murata M, Motohashi Y, Nakano S, Uchida K, Maruyama C, Kyotani S, Tsushima M: The ratio of serum paraoxonase/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192). J Atheroscler Thromb, 2003; 10: 337-342
27. Gensini GG. The coronary artery disease scoring and retrieval system of Gensini (Cardscores). In: Coronary arteriography, pp 271-274, Futura Publishing Company, Inc, Mount Kisco, NY, 1975
28. Soydinc S, Davutoglu V, Dundar A, Aksoy M: Relationship between aortic valve sclerosis and the extent of coronary artery disease in patients undergoing diagnostic coronary angiography. Cardiology, 2006; 106: 277-282
29. Gan KN, Smolen A, Eckerson HW, La Du BN: Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos, 1991; 19: 100-106
30. Billecke S, Draganov DI, Counsell R, Stetson P, Watson C, Hsu C, La Du BN: Human serum paraoxonases isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos, 2000; 28: 1335-1342
31. Elman GL, Courtney D, Andres V, Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 1961; 7: 88-95
32. Pinizzotto M, Castillo E, Fiaux M, Temier E, Gaillard RC, Ruiz J: Paraoxanase-2 polymorphisms are associated with diabetic nephropathy in Type II diabetes. Diabetologia, 2001; 44: 104-107
33. Jakubowski H, Ambrosius WT, Pratt JH: Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Letters, 2001; 491: 35-39
34. Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Ben Hamda K, Ben Farhat M, Miled A, Hammami M: Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem, 2009; 42: 771-776
35. Ginsberg G, Neafsey P, Hattis D, Guyton KZ, Johns DO, Sonawane B: Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity. J Toxicol Environ Health B Crit Rev, 2009; 12: 473-507
36. Bayrak A, Bayrak T, Demirpence E, Kilinc K: Differential hydrolysis of homocysteine thiolactone by purified human serum 192Q and 192R PON1 isoenzymes J Chromatogr B Analyt Technol Biomed Life Sci, 2011; 879: 49-55
37. Serrato M, Marian AJ: A variant of human paraoxonase/ arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest, 1995; 96: 3005-3006
38. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C: The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest, 1996; 98: 883-885
39. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998; 394: 284-287
40. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G: Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab, 2004; 89: 2957-2962
41. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI: Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci, 2000; 98: 355-363
42. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI: Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest, 2002; 32: 259-264
43. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW: Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis, 2001; 155: 229-235
44. Blatter Garin MC, Moren X, J RW: Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res, 2005; 47: 515-520
45. Zheng L, Nukuna B, Brennan ML, Hazen SL: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest, 2004; 114: 529-541
46. Aviram M: Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today, 1999; 5: 381-386
47. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res, 2000; 41: 1481-1494
48. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res, 2000; 41: 1495-1508
49. Harangi M, Seres I, Harangi J, Paragh G. Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment. Cardiovasc Drugs Ther, 2009: 23; 501-510